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1 |  INTRODUCTION
Kidney diseases pose a global health burden with their 
steadily increasing incidence.1-5 Elucidating the efficacy of 
renoprotective strategies is essential en route to novel treat-
ment options and effective prophylactic regimens for acute 
kidney injury (AKI) and chronic kidney diseases (CKD).6 
Current AKI and CKD therapies and prevention strategies are 
largely experience driven.7 Today's options for targeted and 
stratified measures are disappointingly sparse.8 Translational 
approaches—although urgently warranted—are scarce. One 
major obstacle is the technology required to non-invasively 
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Abstract
Damage to the kidney substantially reduces life expectancy. Renal tissue hypoperfu-
sion and hypoxia are key elements in the pathophysiology of acute kidney injury and 
its progression to chronic kidney disease. In vivo assessment of renal haemodynam-
ics and tissue oxygenation remains a challenge. Blood oxygenation level–dependent 
(BOLD) magnetic resonance imaging (MRI) is sensitive to changes in the effective 
transversal relaxation time (T2*) in vivo, and is non-invasive and indicative of renal 
tissue oxygenation. However, the renal T2* to tissue pO2 relationship is not governed 
exclusively by renal blood oxygenation, but is affected by physiological confounders 
with alterations in renal blood volume fraction (BVf) being of particular relevance. 
To decipher this interference probing renal BVf is essential for the pursuit of renal 
MR oximetry. Superparamagnetic iron oxide nanoparticle (USPIO) preparations can 
be used as MRI visible blood pool markers for detailing alterations in BVf. This re-
view promotes the opportunities of MRI-based assessment of renal BVf. Following 
an outline on the specifics of renal oxygenation and perfusion, changes in renal BVf 
upon interventions and their potential impact on renal T2* are discussed. We also 
describe the basic principles of renal BVf assessment using ferumoxytol-enhanced 
MRI in the equilibrium concentration regimen. We demonstrate that ferumoxytol does 
not alter control of renal haemodynamics and oxygenation. Preclinical applications of 
ferumoxytol enhanced renal MRI as well as considerations for its clinical implementa-
tion for examining renal BVf changes are provided alongside practical considerations. 
Finally, we explore the future directions of MRI-based assessment of renal BVf.
K E Y W O R D S
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disentangle the pathophysiological complexity of AKI and 
its progression to CKD. Closing this gap asks for approaches, 
which are clinically applicable, ubiquitous and non-inva-
sive—the forte of MRI.9 MRI affords longitudinal studies, 
high anatomic detail, full kidney coverage, soft tissue con-
trast that helps to capture the physiological heterogeneity be-
tween and within the renal layers, and temporal resolution 
ranging from seconds to minutes.9
Renal tissue hypoperfusion and hypoxia play a prominent 
role in the early pathophysiology of AKI and probably also 
promote its progression to CKD.10-16 Hypoxia results from 
an imbalance between oxygen (O2) delivery and O2 con-
sumption.11,14,17-23 Insights into renal oxygenation can be 
derived from blood oxygenation level–dependent (BOLD) 
MRI, which offers a non-invasive in vivo technique.24 Renal 
BOLD-MRI methodology has progressed and a large body of 
literature on (pre)clinical applications25-31 is available. The 
growing number of reports eloquently speaking about renal 
BOLD-MRI and the consensus papers on technical recom-
mendations32 document the value of non-invasive MRI to 
renal (patho)physiology. In BOLD MRI image contrast is 
sensitive to bulk microscopic magnetic field perturbations, 
which are caused by paramagnetic deoxygenated haemoglo-
bin (deoxyHb) and impact the effective transversal MR relax-
ation time T2*.33 T2* weighted MRI is sensitive to changes in 
the amount of deoxyHb per tissue volume element (voxel).34 
T2* decreases if the volume fraction of deoxyHb increases. 
Renal T2* or its reciprocal value (R2*=1/T2*) is a surrogate 
of renal blood oxygenation, but is frequently interpreted also 
as a surrogate of renal tissue oxygenation. This assumption 
is based upon the T2* dependence on O2 saturation of Hb 
(StO2), the physiological relationships between StO2 and 
blood partial pressure of O2 (pO2), and between blood pO2 
and tissue pO2. Mapping of T2* or of R2* has been employed 
for the assessment of renal oxygenation in a broad spectrum 
of renal tissue states and interventions in human and animal 
studies.29,35 Renal T2* has even been suggested to display a 
close correlation with renal tissue pO2 levels.36
Notwithstanding the encouraging progress made, ques-
tions have been raised regarding the correct interpretation of 
BOLD MRI data in the kidney as a surrogate of tissue oxy-
genation. These questions spurred the debate on “how bold is 
BOLD-MRI of the kidney?”.24 This debate was triggered by 
experimental observations derived from simultaneous mea-
surements of renal T2* and tissue pO2 using an integrated ap-
proach of MRI and gold standard physiological measurements 
(MR-PHYSIOL).37-39 MR-PHYSIOL experiments revealed 
substantial discrepancies in the quantitative relationship be-
tween changes in renal T2* and those in renal tissue pO2 for 
the different layers of the kidney (cortex, outer medulla, inner 
medulla) and for various (patho)physiologically relevant in-
terventions to the kidney.38 In essence, the integrated MR-
PHYSIOL approach confirmed that the renal T2* to tissue 
pO2 relationship is not governed exclusively by renal blood 
oxygenation, but is also heavily influenced by a number of 
physiological confounders as illustrated in Figure 1.
Of particular relevance are alterations in renal blood vol-
ume fraction (BVf). As renal T2* is a surrogate for the amount 
F I G U R E  1  Schematic overview of the 
relationship between tissue partial pressure 
of oxygen (pO2) and renal T2*, together with 
the confounding key factors. This includes 
T2* alterations as a result of changes in the 
tubular compartment and/or in the intrarenal 
vascular compartment. Changes in the renal 
blood volume fraction induced by either 
active vasomotion or passive circular vessel 
distension/compression alter the amount 
of deoxyHb per tissue volume and may 
confound T2*. As the renal capsule has a 
rather low elasticity, changes in tubular 
volume fraction will often result in circular 
distension or compression of intrarenal 
vessels, which will inevitably induce 
changes in the renal blood volume fraction 
which may confound T2*
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of deoxyHb per tissue volume, any change in BVf confounds 
the interpretation of T2* changes commonly exclusively at-
tributed to alterations in blood oxygenation, and even more so 
as tissue oxygenation. This confounding role of BVf has not 
received careful consideration and assessment so far, although 
it was recently outlined in reports on alterations in renal vascu-
lar conductance, local haemoglobin concentrations and kidney 
size triggered by physiological interventions.40 The impact of 
renal BVf changes on T2* exceeds that of most other organs 
as a result of the substantial and readily alterable blood vol-
ume fraction in the renal cortex.41 Taking this into account, T2* 
mapping alone cannot provide an unambiguous examination of 
renal oxygenation. However, if an assessment of renal BVf is in-
tegrated into a comprehensive MR imaging protocol, the com-
bination of renal T2* and BVf mapping could provide a more 
quantitative surrogate of renal blood oxygenation en route to 
MR oximetry tailored for the in vivo and non-invasive charac-
terization of renal tissue oxygenation and haemodynamics.24,42
Realizing the opportunities, challenges and caveats of 
assessing renal haemodynamics and tissue oxygenation in 
vivo and non-invasively, probing renal BVf is highly rele-
vant if not essential for the pursuit of renal MR oximetry.42 
Intravenously applied superparamagnetic iron oxide nanopar-
ticle (USPIO) preparations can be used as MRI visible blood 
pool markers for probing alterations in BVf, in particular 
ferumoxytol, which is increasingly used off-label as an in-
travascular MRI contrast agent.42-47 To promote these ad-
vancements at the interface between physics, physiology and 
patient care, this review discusses the opportunities of feru-
moxytol-enhanced assessment of renal BVf. For this purpose, 
the specifics of renal oxygenation and perfusion are outlined 
first. Secondly, alterations in renal BVf upon interventions 
and their impact on T2* are surveyed. The basic physical and 
biophysical principles of probing BVf using ferumoxytol as 
a blood pool marker are then described. Next, acute effects 
of ferumoxytol on controlling renal haemodynamics and 
oxygenation are considered. Preclinical applications of feru-
moxytol-enhanced MRI are presented for monitoring of renal 
BVf in physiological settings where significant variations in 
both, renal BVf and oxygenation, occur. Considerations for 
clinical implementation of ferumoxytol-based assessment of 
renal BVf changes are provided. We conclude by exploring 
future directions of MRI-based assessment of renal BVf.
All the animal experiments performed by the authors and 
shown in the figures were carried out in accordance with pub-
lished guidelines.48,49
2 |  SPECIFICS OF RENAL 
PERFUSION AND OXYGENATION
Renal haemodynamics and oxygenation offer a num-
ber of striking differences when compared with non-renal 
tissue.24,38 First, total renal blood flow (RBF) is huge when 
compared with virtually all other organs: the kidneys receive 
about 20% of the cardiac output under resting conditions. 
Accordingly, the kidneys’ oxygen extraction (the difference 
between the O2 content in the renal arterial and the renal 
venous blood) is low. Yet blood perfusion within the kid-
neys is quite heterogeneous: while 100% reaches the cortex, 
only 15% of blood that previously passes through the cor-
tex will reach the medulla. This unequal distribution is one 
reason behind the very low pO2 in the medulla. Secondly, 
the kidney differs from all other organs with regard to the 
relationship between metabolism and perfusion. More than 
26 thousand millimoles of sodium (Na+) are filtered in the 
human glomeruli every day: this is equivalent to more than 
1.5 kg of table salt. To achieve sodium balance, the amount 
of salt excreted via the urine must exactly match the amount 
of ingested salt minus that amount of extrarenal loss. Thus, 
more than 99% of the filtered sodium must usually be re-
absorbed from the tubules. Tubular resorption relies on ac-
tive transport processes, which account for about 90% of the 
kidney's energy expenditure, and, thus, its O2 consumption. 
The more Na+ is filtered in the glomeruli, the more must 
be reabsorbed. As glomerular filtration rate (GFR), in gen-
eral, increases with increased renal blood flow, renal O2 
consumption also usually increases with increased renal per-
fusion. This is in contrast to all other organs, where metabo-
lism determines perfusion. However, the kidney is equipped 
with efficient mechanisms of autoregulation, that is, the abil-
ity to maintain RBF and GFR relatively constant in the face 
of changes in renal artery pressure. Renal autoregulation is 
suggested to serve the purpose of balancing O2 delivery, that 
is, RBF, with the metabolic needs and O2 demands arising 
from tubular reabsorption.
In addition to the heterogeneous intrarenal blood perfusion, 
other factors substantially contribute to the low tissue pO2 
and, in particular, the physiological hypoxia in the medulla 
as summarized in a recent review.24 First, there is a consider-
able shunt diffusion of O2 from arteries to veins in the cortex 
and from descending to ascending vasa recta in the medulla. 
Second, the Fahræus-Lindqvist effect reduces the haematocrit 
in the vasa recta supplying the medulla, which results in a 
reduction in the O2 content of blood perfusing the medulla. 
Third, plasma skimming at intrarenal vessel branches induces 
different haematocrit and O2 content of blood perfusing the 
daughter vessels.
3 |  ALTERATIONS IN RENAL BVF 
UPON INTERVENTIONS AND THEIR 
IMPACT ON T2*
Changes in renal BVf, that is, in vessel volume per tissue vol-
ume, induced by either active vasomotion or passive circular 
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vessel distension/compression alter the amount of deoxyHb per 
tissue volume and thus confound the renal T2* to tissue pO2 re-
lationship (see Figure 1).50 If considered per tissue weight, total 
renal blood flow is much higher than that of most other tissues. 
It is to be expected that renal vasomotion, at least of cortical ves-
sels, results in renal BVf changes that exceed those documented 
for other tissues.10,21,32,35 Substantial changes in the renal BVf 
were observed for various experimental settings.7,11,20 Moreover, 
the tubules are a unique feature of the kidney. Their volume frac-
tion is quite large and can rapidly change as a result of changes 
in glomerular filtration, alterations in tubular outflow towards the 
pelvis, changes in tubular fluid resorption and modulation of the 
transmural pressure gradient. As the renal capsule has a rather 
low elasticity, changes in tubular volume fraction should often 
result in circular distension or compression of intrarenal vessels, 
which will inevitably change the renal BVf.10
Figure 1 provides a schematic overview of the confound-
ers of the renal T2* to tissue pO2 relationship as derived from 
various studies, in particular studies that assessed the impact 
of alterations in renal haemodynamics, renal blood and tissue 
oxygenation, haematocrit, and tubular and vascular volume 
fractions on T2* under various (patho)physiological condi-
tions.24 The confounders include (i) changes in O2 diffusion 
between blood and tissue, (ii) shifts of the oxyHb dissociation 
curve, (iii) alterations in Hb concentration per blood volume 
(haematocrit), (iv) changes in the tubular compartment and (v) 
changes in the intrarenal vascular compartment (blood volume 
fraction, BVf). The impact of changes in BVf was demon-
strated in pre-clinical studies that revealed suprarenal aortic 
occlusion (or that of the renal artery) induces only a minor de-
crease in renal T2*, in contrast to a massive T2* decrease upon 
occlusion of the renal vein.24 Simultaneous occlusion of the 
renal vein and artery yielded an intermediate T2* decrease.24 
In each of these three cases, tissue pO2, blood pO2 and StO2 
approach zero. Yet the BVf is decreased in case of arterial 
occlusion, augmented for venous occlusion and remains ap-
proximately unchanged during common arterio-venous oc-
clusion. Contrary to vasoconstriction, vasodilation induces 
T2* shortening governed by a BVf increase, although renal 
tissue pO2, blood pO2, and StO2 primarily increase owing to 
improved O2 delivery. Vasoconstriction causes a T2* prolon-
gation despite a decline in O2 delivery as a result of a reduced 
BVf. Distension of tubules results in increased T2* in the face 
of primarily unchanged StO2, blood and tissue pO2 caused by 
reduced BVf.24 Anaemia or an increase in plasma skimming 
evoke an increase in T2* despite the drop in O2 delivery and 
tissue pO2. Finally, alterations in the inspiratory O2 fraction 
(FiO2) change renal T2*. Hypoxia decreases T2* in parallel 
with StO2, blood and tissue pO2. Changes in BVf may either 
enhance or diminish this effect on T2*, depending on whether 
the FiO2 falls moderately or severely below 21%, leading ei-
ther to intrarenal vasodilation or vasoconstriction respectively. 
The effect of hyperoxia on T2* is much less pronounced.
4 |  BASIC PRINCIPLES OF 
RENAL BVF ASSESSMENT 
USING FERUMOXYTOL IN AN 
EQUILIBRIUM CONCENTRATION 
REGIMEN
Ferumoxytol-enhanced MRI is susceptible to bulk micro-
scopic magnetic field perturbations around blood vessels, 
which are induced by the USPIO nanoparticles. These mi-
croscopic magnetic field inhomogeneities affect the (ef-
fective) transversal MR relaxation times T2* and T2 as a 
function of the USPIO concentration. T2* is governed by 
1/T2* = 1/T2 + 1/T2', with T2 being the tissue-dependent 
transverse relaxation time observed in spin-echo MR meas-
urements and T2' embodying susceptibility-related contri-
butions.51 While the magnetic field perturbations caused 
by Fe atoms (in deoxyHb or USPIO nanoparticles) directly 
reduce T2*, diffusion effects in the proximity of blood ves-
sels also lead to a decrease in T2. When the USPIO con-
centration increases, a T2*/T2 decrease occurs and hence 
a signal attenuation in T2*-weighted and T2-weighted MR 
images. Parametric mapping provides quantitative data of 
the relaxation times T2* and T2. Renal T2* maps are com-
monly obtained with multi-echo gradient echo techniques. 
With this approach a train of gradient refocused echoes is 
acquired after the initial excitation, whereby each echo is 
independently T2* weighted. In vivo T2* mapping of the 
kidney permits high anatomical detail employing an in-
plane spatial resolution as good as 50-100 μm in mice and 
about 250 μm in rats with dedicated small animal MR sys-
tems equipped with state-of-the-art radiofrequency antenna 
technology52 (Figure 2). Parametric mapping of the recip-
rocal value of renal T2* (R2*=1/T2*) is used for renal BVf 
mapping in an equilibrium concentration regimen. For this 
purpose, renal BVf can be calculated by comparing pre-
ferumoxytol data (R2*-maps) with post-ferumoxytol data 
(R2*USPIO maps):53
where γ is the gyromagnetic ratio, which is 2.675 · 108 rad/
(s T), B0  =  9.4  T and ΔχUSPIO is the susceptibility dif-
ference between blood with and without added USPIO: 
ΔχUSPIO = 0.024 ppm (cgs units) × [USPIO dose in mg Fe/
kg body weight].54 The equilibrium concentration regimen fa-
cilitates the monitoring of renal BVf over several hours, sup-
ported by the long half-life time of ferumoxytol.55 Assuming 
that the magnetic field inhomogeneity is negligible and con-
stant throughout the experiment so that R2* is governed by 
microscopic rather than by macroscopic susceptibility gra-
dients, renal StO2 can be estimated using a multi-parametric 
(1)
BVf =
3
4휋
⋅
(
R∗
2,USPIO
−R∗
2
)
Δ휒USPIO ⋅B0 ⋅훾
=
3
4휋
⋅
ΔR∗
2,USPIO
Δ휒USPIO ⋅B0 ⋅훾
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MR approach including renal R2*, R2 and BVf and a solution 
of the model equation s(t) = f(t, BVf, SO2,...) for StO2 = f(R2*, 
R2, BVf,...)56-58:
with Δχ0 representing the susceptibility difference between de-
oxygenated and oxygenated red blood cells (Δχ0 = 0.264 ppm 
at a magnetic field strength of B0 = 9.4 tesla).59 StO2 is given 
in arbitrary units as magnetic field inhomogeneities B0 are not 
corrected. A haematocrit of Hct = 0.40 can be used for the renal 
cortex and for the outer medulla (85%-95% of systemic Hct, 
which was assumed to be 0.45).60
Further to the equilibrium concentration regimen, renal 
blood volume can also be derived from dynamic suscep-
tibility weighted imaging, where signal intensity changes 
in the kidney are monitored during the first passage of a 
ferumoxytol bolus as demonstrated in human studies.61 
This approach requires the measurement of the arterial 
concentration-signal-intensity-time-curve of ferumoxy-
tol, designated as the arterial input function (AIF) and its 
deconvolution from the renal tissue signal intensity time 
curves. This technique is better suited for clinical applica-
tions than preclinical studies in small animals, where the 
small size of the relevant vessels makes the AIF measure-
ment rather challenging.
5 |  FERUMOXYTOL DOES 
NOT AFFECT REGULATION OF 
RENAL HAEMODYNAMICS AND 
OXYGENATION
Ferumoxytol is an approved intravascular iron supplemen-
tation therapy in the USA targeting patients with iron defi-
ciency anaemia related to CKD. The preparation consists of 
USPIO nanoparticles encapsulated by a polyglucose sorbi-
tol carboxymethylether coating. Ferumoxytol is superpara-
magnetic, which makes it a viable candidate as an off-label 
MRI contrast agent for a broad spectrum of preclinical and 
diagnostic imaging applications.44,45,62 Ferumoxytol does not 
readily extravasate and is not filtered in the glomeruli, so it 
exhibits a long intravascular half-life of > 14 h in humans 
and about 2 h in small rodents. Ferumoxytol can be adminis-
tered by intravenous injection.
A recent report studied acute intrinsic effects of feru-
moxytol on the control of renal haemodynamics and oxy-
genation in rats.63 This study was of high relevance as basic 
methodological principles require that a method intended 
to measure a certain variable per se does not alter this 
variable. For this purpose, in vivo measurements of arte-
rial blood pressure, total renal blood flow (RBF, transsonic 
probe), local perfusion (laser-Doppler-flux) and tissue pO2 
(fluorescence quenching optodes) in the renal cortex and 
medulla of healthy rats were employed upon application of 
ferumoxytol.20,63,64 Modulation of renal haemodynamics 
(2)StO2≈1−
(
3
4휋
⋅
(
R∗
2
−R2
)
훾 ⋅Δ휒0 ⋅BVf ⋅Hct ⋅B0
)
F I G U R E  2  Coronal views of rat kidneys: (A) photograph of a freshly excised rat kidney, (B) T1-weighted anatomical MR image acquired ex 
vivo using an in-plane spatial resolution of 50 μm (cortex COR; outer medulla OM; inner medulla IM, the 1 cm scale bar illustrates the size of the 
rat kidney), (C) T2*-sensitized MR image acquired ex vivo using an in-plane spatial resolution spatial resolution 50 μm, (D) T2*-weighted in vivo 
MR image acquired with an in-plane spatial resolution of 300 μm prior to ferumoxytol application, (E) T2*-weighted in vivo MR image acquired 
with an in-plane spatial resolution of 300 μm after ferumoxytol application, (F) in vivo T2* map acquired at baseline with an in-plane spatial 
resolution of 300 μm and (G) in vivo T2* map acquired post–ferumoxytol administration with an in-plane spatial resolution of 300 μm. The T2* 
shortening caused by the superparamagnetic effect of ferumoxytol can be readily recognized
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and oxygenation was accomplished by dedicated test in-
terventions.63 The dose study included three (cumulative) 
doses of ferumoxytol: two low doses adapted from previous 
reports on monitoring the blood volume fraction of the brain 
and kidneys in rats, and a high-dose regimen that mimics 
the human equivalent dose (based upon body surface area) 
for the therapeutic application of ferumoxytol.63 The main 
finding of these investigations in rats was that intravenously 
injected ferumoxytol has no sustained impact on renal hae-
modynamics and oxygenation under baseline physiological 
conditions as well as on control of haemodynamics and ox-
ygenation as studied by hypoxic and hyperoxic stimuli and 
a brief suprarenal aortic occlusion (Figure 3).63 The only 
significant finding reported was a moderate reduction in the 
hyperoxia-evoked increase in arterial pressure at a cumu-
lative dose of 41 mg Fe/kg. This dose mimics the human 
equivalent dose for iron supplementation and is well be-
yond the dose commonly used for MR-based assessment 
of the renal BVf. The results demonstrated no immediate 
risk of impaired control of renal oxygenation or perfusion 
upon application of ferumoxytol. This observation rendered 
ferumoxytol as an intravascular contrast medium suitable 
for the quantification and monitoring of changes in renal 
blood volume fraction.63
6 |  MONITORING RENAL 
BVF DURING EXPERIMENTAL 
PHYSIOLOGICAL INTERVENTIONS
The applicability of ferumoxytol-enhanced MRI for prob-
ing renal BVf during physiological interventions that are 
concomitant with variations in BVf was recently demon-
strated in healthy rats in conjunction with correcting renal 
T2* for BVf alterations.42 For this purpose a dose finding 
study was performed first in rats to ensure that BOLD ef-
fects were detectable after ferumoxytol administration 
considering that the signal-to-noise ratio may be further 
diminished owing to T2* shortening attributed to the de-
oxygenation of blood.42 Balancing the sensitivity of T2* to 
ferumoxytol injection and the T2* sensitivity to the (patho)
physiological intervention (occlusion of the renal vein) a 
F I G U R E  3  Assessment of acute 
effects of ferumoxytol on the control of 
renal haemodynamics and oxygenation 
as studied by a brief occlusion of the 
suprarenal aorta and during recovery.63 
Ferumoxytol does not influence 
physiological changes during suprarenal 
aortic occlusion and recovery. Shown are 
relative changes in renal perfusion pressure, 
total renal blood flow (Transonic probe), 
cortical and medullary tissue perfusion 
(Flux, laser-Doppler-flux probes), and 
cortical and medullary tissue oxygen tension 
(pO2, fluorescence-quenching probes) 
upon injection of isotonic saline (volume 
Control), and three consecutive injections 
of ferumoxytol to achieve cumulative doses 
of 6, 10 and 41 mg Fe/kg body mass (6 FO, 
10 FO and 41 FO). Data are presented as 
mean ± SEM
   | 7 of 14NIENDORF Et al.
ferumoxytol dose of 2-4  mg Fe/kg BW was found to be 
best suited for R2*, BVf and StO2 mapping. ΔR2 and ΔR2* 
analyses revealed that BVf is higher in the outer medulla 
versus the renal cortex (Figure 4).42
Changes in the intrarenal BVf and StO2 were studied 
in rats in response to renal venous occlusion. Examples of 
renal cortical and outer medullary T2* maps are depicted 
in Figure 5. Renal BVf and StO2 maps obtained at baseline, 
during renal venous occlusion and during the recovery phase 
are illustrated in Figure 5. BVf and StO2 derived from MRI 
in rats were benchmarked against BVf and StO2 references 
provided by near infrared spectroscopy (NIRS) conducted in 
rats. The MRI data were in qualitative accordance with the 
NIRS data: cortical StO2 dropped substantially during the 
short-term venous occlusion for both approaches. The almost 
twofold increase in cortical BVf deduced from MRI during 
venous occlusion was in qualitative agreement with the rise 
in haemoglobin concentration per tissue volume derived 
from NIRS.
The main findings of the assessment of renal BVf during 
experimental physiological interventions in rats at 9.4 Tesla 
were fourfold42: (i) a 4 mg Fe/kg dose of ferumoxytol suits 
BVf assessment at 9.4 T during baseline, venous occlusion and 
recovery, (ii) the proposed approach permits reproducibility 
for BVf and StO2 examination as validated by test/re-test ex-
periments,42 (iii) relative changes in cortical BVf and cortical 
StO2 derived from MRI were in qualitative accordance with 
relative changes in BVf and StO2 deduced from NIRS and 
(iv) without the monitoring of BVf MRI overestimates the 
StO2 decrease during renal venous occlusion.42 To conclude, 
this experimental work permitted a non-invasive detection 
of renal BVf increase in rats upon venous occlusion and a 
removal of its effects on blood oxygenation-sensitized renal 
MR.
Probing renal BVf with ferumoxytol-enhanced MRI 
can be integrated with gold standard physiological mea-
surements such as MR-PHYSIOL.37-39 The insertion of in-
vasive probes (combined pO2- and laser-flux probes) into 
the kidney in the preclinical hybrid MR-PHYSIOL setting 
might induce a minor change in the intrarenal (tubular and 
blood) volume fractions. The volume of a kidney in the 
rats we usually study ranges between 1200 μl and 1500 μl. 
The combined volumes of two probes inserted (usually 
one into the cortex, one into the medulla) ranges between 
30 μl and 50 μl. The amount of tissue (including the tubu-
lar and blood volume) “displaced” by two probes is about 
2%-4%. This “volume shift” can be neglected for renal BVf 
assessment.
F I G U R E  4  Illustration of blood volume measurement procedure using ferumoxytol as an exogenous blood pool marker. Shown are 
parametric maps of renal R2 and R2* prior (left) to and after (middle) ferumoxytol administration.42 Quantitative R2 and R2* maps permit 
comparisons over time and between animals, as they are not biased by external factors such as the RF coil sensitivity (B1-) or the location of the 
subject with respect to the RF coil. The difference between R2/R2* maps acquired before and after USPIO is closely related to the local BVf. The 
area with apparently very high BVf stretches from the papilla via the inner medulla to the central outer medulla. This phenomenon represents the 
influence of large iron-rich vessels located close to the image slice, rather than the actual medullary tissue properties. The locations of apparently 
high BVf in papilla and inner medulla co-localize with the renal artery and vein, and the interlobar arteries and veins
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F I G U R E  5  Maps of renal cortical and outer medullary T2*, together with estimated maps of blood volume fraction (BVf) and oxygen 
saturation of Hb (SO2) at baseline, during renal venous occlusion and the recovery phase.42 The maps at baseline and after 10 minutes of recovery 
are almost indistinguishable, confirming that the effects of venous occlusion were reversible. Within-subject repeatability is demonstrated for renal 
BVf and SO2 by comparing the maps derived from two different experimental phases, namely, following 4 mg Fe/kg USPIO and following 6 mg 
Fe/kg USPIO. Test-retest reliability (repeatability) was high—the differences between both iterations are nearly negligible, even though more 
USPIO had been injected in between. In addition, SO2 maps were calculated assuming that renal BVf remains constant and identical to the baseline 
condition (bottom row): the missing compensation for BVf changes during venous occlusion results in SO2 values considerably lower than when 
BVf was monitored
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Notwithstanding these encouraging first results, bench-
marking BVf and StO2 results deduced from MRI against a 
quantitative reference is essential for further rigorous valida-
tion of the MRI approach. Currently, a perfect quantitative 
equivalent for validation of renal MR-derived BVf and StO2 
is not readily available. Invasive tissue pO2 probes are very 
well established but cover very small renal regions. Another 
constraint is that invasive tissue pO2 probes measure tissue 
pO2 rather than blood oxygenation. NIRS affords estimation 
of StO2 and tissue concentration of haemoglobin—an estab-
lished surrogate for BVf—but the necessary mathematical 
modelling is rather complex and it is currently constrained 
to reflection mode probing of the renal cortex because of 
penetration depth limitations. However, benchmarking the 
occlusion-induced changes in cortical BVf and StO2 derived 
from MRI with NIRS obtained for the renal cortex show good 
agreement. This observation provides encouragement for fur-
ther advancement and integration of the MR approach into a 
comprehensive renal MR oximetry protocol.
7 |  TOWARDS CLINICAL 
IMPLEMENTATION OF 
FERUMOXYTOL -ENHANCED MRI 
ASSESSMENT OF RENAL BVF
The R2 and R2* mapping protocols employed for renal BVf 
assessment in small rodents at ultrahigh magnetic field 
strengths are readily available on clinical MR scanners, which 
facilitates a swift translation into clinical use of ferumoxytol-
based renal BVf examination. This development is fuelled by 
an ever-growing number of studies that report on the off-la-
bel use of ferumoxytol for a wide portfolio of preclinical and 
diagnostic imaging applications. In a clinical setting, renal 
T2* and T2 mapping is commonly employed at time points 
that are longitudinally propagated by at least hours if not days 
or months. With this clinical context, a temporal resolution of 
2-3 min for combined T2* and T2 mapping and the 1-2 min 
time shift between the measurements of both parameters are 
negligible. MRI protocols affording breath-hold acquisitions 
facilitated by accelerated imaging using parallel acquisition 
techniques or compressed sensing approaches would make 
respiratory triggering obsolete, shorten examination times 
and enhance image quality by reducing the propensity to res-
piratory motion-induced image artefacts.
En route to clinical implementation ferumoxytol was 
demonstrated to be useful for differentiation between acute 
and chronic inflammatory kidney diseases based on differ-
ent patterns of parenchymal ferumoxytol depositions in a 
rat model using a clinical whole-body 3.0 T MR scanner.65 
The sensitivity of ferumoxytol-enhanced R2* mapping to dy-
namic BVf changes in the rat kidney was demonstrated using 
a 3.0 Tesla human MR scanner.66
Steady-state MR angiography using incremental doses of 
up to 4 mg/kg body weight of ferumoxytol as intravenous con-
trast agent was performed in patients with advanced kidney 
disease due for transplant listing, which implicitly supports 
the feasibility of renal BVf mapping in patients.67 T2* map-
ping has been also used to demonstrate that allografts under-
going acute rejection in paediatric kidney transplant patients 
show T2* prolongation in ferumoxytol-enhanced MRI versus 
non-rejecting allografts.68 This observation was attributed 
to reduced perfusion and increased oedema in rejecting al-
lografts.68 Normal R2* values obtained for post-ferumoxytol 
administration (4 mg/kg body weight) at 1.5 T and 3.0 T were 
reported for the human kidney.69 Pharmacokinetics of feru-
moxytol in the kidney were examined in healthy subjects using 
R2* relaxometry at 1.5 T and 3.0 T. 70 Renal R2* increased 
at post-injection and peaked on day 1 (R2*baseline = 13 s−1 vs 
R2*ferumoxytol = 31 s−1).70 Clearance of ferumoxytol from the 
kidney occurred on day 2 for a ferumoxytol dose of 2mg/
kg body weight. For a ferumoxydol dose of 4mg/kg body 
weight clearance from the kidney was reported on day 4 
post-injection.70 Renal T2* decrease caused by ferumoxytol 
accumulation was demonstrated for healthy subjects and for 
type 1 diabetes patients.71 A recent multicentre safety study 
enrolled 3215 patients who received 4240 ferumoxytol injec-
tions (dose range: 1–11 mg/ kg body weight) for MRI.72 The 
authors reported a positive safety profile for ferumoxytol use 
in MRI and concluded that diagnostic ferumoxytol was well 
tolerated and associated with no serious adverse events.72 
Ferumoxytol-enhanced dynamic MRI was employed in 
healthy subjects to assess the blood volume in the renal cor-
tex (mean rBVrenal cortex  =  41±8  ml/100  g).61 When imple-
menting ferumoxytol-based renal BVf assessment in clinical 
renal imaging protocols, caution should be taken to prevent 
interference of ferumoxytol with other MRI techniques and 
MR contrasts. For example, ferumoxytol shortens the longi-
tudinal relaxation time T1, which affects T1 contrast.
Application of ferumoxytol might impact mapping of re-
gional perfusion in renal tissue using arterial spin labelling 
(ASL) techniques.30,73-75 The ASL technique employs mag-
netization-labelled water in arterial blood of the aorta or the 
renal arteries as a freely diffusible endogenous tracer. In a 
preparation module, spin labelling is applied to tag the longi-
tudinal magnetization of arterial blood water before it enters 
the imaging plane in the kidney. An image covering the kid-
ney is acquired following arterial blood labelling and a delay 
time between labelling and the advent of the tagged arterial 
blood water in the imaging plane. A control image is acquired 
of the same slice in the kidney using the same delay time 
but no labelling of the arterial blood water. Provided that the 
magnetization of the inflowing blood is the only difference 
between the control and the label image, a difference map 
yields a perfusion-weighted image of the kidney with the 
signal intensity being proportional to renal tissue perfusion. 
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T1 shortening owing to the presence of ferumoxytol requires 
adaption of the delay or traveling time used for arterial blood 
water in the arterial spin labelling preparation module. ASL 
apporaches were exploited for examination of regional renal 
blood flow and were shown to be suitable for the evaluation 
of renal injury in rats76 and for the assessment of patients suf-
fering from diabetes and moderate (stage 3) CKD compared 
with healthy controls.30 ASL MRI also provides an avenue 
towards MR-based assessment of arterial blood volume using 
multiple-delay time sampling as demonstrated for the human 
brain.77 As ASL is a difference image technique and a low 
signal-to-noise ratio (SNR) technique, it might suffer from 
ferumoxytol-induced T2* shortening and SNR degradation. 
To decouple the interference of ferumoxytol with other MR 
techniques and MR contrasts, it is thus recommended that 
ferumoxytol-enhanced BVf assessments be performed at the 
end of clinical renal MRI protocols.
8 |  FUTURE DIRECTIONS OF 
MAPPING RENAL BVF WITH MRI
Due caution for quantitative interpretation of renal BOLD-
MRI is required as renal T2* is a surrogate that does not 
quantitatively reflect renal tissue oxygenation in several 
(patho) physiological conditions and because T2* may not 
mirror blood oxygenation quantitatively in some scenarios. 
This requires that renal blood oxygenation level–related 
T2* changes are strictly differentiated from T2* alterations 
caused by changes in tubular and vasculature volume frac-
tion, the latter being T2* confounders.38 To meet this goal, it 
is essential to incorporate an MR-based assessment of renal 
BVf into renal MRI protocols to detail vasodilation, vasocon-
striction and other alterations in the blood volume fraction.24
It is well recognized that dynamic contrast-enhanced 
(DCE) methods in conjunction with tracer kinetic principles 
provide a viable alternative for the quantification of renal 
perfusion and blood volume.29,78-81 For this purpose, bolus 
injection of exogenous contrast agents like gadolinium (Gd) 
chelates or iron oxide nanoparticles is administered.82-85 
Tracking and analysing the dynamic susceptibility contrast 
(DSC) changes during first-pass contrast agent bolus passage 
through the kidney requires fast imaging techniques with a 
temporal resolution of ≤  1  s. It also requires the measure-
ment of the arterial concentration-time-curve, designated 
as the arterial input function and its deconvolution from the 
time course of signal intensity in renal tissue. Renal DSC was 
successfully implemented in human studies and animal stud-
ies.80,82-85 For the latter, methodological (imaging speed) and 
physiological (heart rate) constraints govern the achievable 
spatial resolution and render this approach particularly chal-
lenging in small rodents. Compartmental models used for the 
analysis of DCE signal intensity time course upon injection 
of a gadolinium-based contrast bolus commonly include an 
extravascular component, leading to a complex mathemat-
ical kinetic description. Intravascularly confined contrast 
agents benefit DCE MRI as their kinetic models exclude 
the extravascular space. The experimental paramagnetic 
gadolinium-based contrast agent P792 is a rapid-clearance 
intravascularly confined agent characterized by negligible in-
terstitial diffusion but unrestricted glomerular filtration.86-88 
This intravascular contrast agent has recently been evalu-
ated for measurements of renal function in rats using a low 
dosage.89
Fluorine (19F) MRI offers an intriguing alternative to pro-
ton (1H) methods such as T2* and DCE imaging/mapping for 
quantifying changes in blood pO2 and blood volume in the 
kidney. 19F is another MR active nucleus with similar sensitiv-
ity to 1H. Although the absence of organic 19F in the body of 
humans and rodents is an advantage and any 19F compounds 
introduced in vivo can be detected with high selectivity and 
absolute specificity, its application is also challenged by typ-
ically low SNRs, especially when 19F compounds are admin-
istered systemically and distribute at low concentrations in 
vivo. Nonetheless, the application of fluorinated emulsions, 
typically prepared from perfluorocarbons (PFCs), has been 
explored to study vascular pathology in mice and rats90,91 and 
recently, their utility to assess BVf and pO2 in the renal mi-
crovasculature was demonstrated following AKI in mice.92
Owing to the virtual absence of 19F in the human/animal 
body, 19F spin density–weighted MRI following intravenous 
injection of fluorinated emulsions may provide a quantitative 
measure of renal BVf. Compared with the USPIO-based ap-
proach, BVf assessment using 19F requires a reference with 
known concentration to be scanned together with the subject, 
and the much lower local concentration of 19F vs 1H requires 
measures to counteract the SNR challenge, such as increas-
ing signal averaging and/or lowering spatial resolution. To 
this end, in the context of renal MR oximetry, conceptually 
it is more appealing to exploit directly the blood oxygenation 
sensitivity of PFC (as outlined in the following), rather than 
using it for probing BVf to correct for effects of BVf varia-
tions from T2*-based blood oxygenation measurements.
PFC emulsions have a high oxygen–dissolving capac-
ity making them ideal O2 carriers as well as indicators of 
pO2 changes. The longitudinal relaxation rate (1/T1) of 19F 
in PFCs was shown to depend linearly on O2 partial pres-
sure.93 This led to the first non-invasive in vivo tissue O2 
assessments in tumour tissue and liver in mice94 and later 
in the myocardial tissue of rats.95 The latter study provided 
the first proof-of-concept study for rapid, non-invasive mea-
surements of O2 tension changes in response to ischaemia 
and reperfusion using 19F MRI.95 More recently, a decreased 
renal BVf and blood pO2 was detected in the cortico-med-
ullary junction 24  h following unilateral renal ischaemia 
reperfusion using 19F MRI, and in parallel an increased T2* 
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was observed by 1H BOLD MRI.92 In the injured kidney, the 
T2*, 19F signal and pO2 within the renal cortex were com-
parable with the contralateral non-injured kidney, but in the 
inner medulla, vascular leakage and extravascular retention 
of PFC NPs resulted in reduced T2*, increased 19F and un-
changed pO2. These results suggest a recovery in perfusion 
and oxygenation within the cortex but not within the inner 
medulla.92 This study shows the potential of applying PFC 
emulsions for studying renal disease. The relatively large 
size of the nanoparticles within these emulsions (> 100 nm) 
might provide a relatively good safety profile with respect 
to renal toxicity, as they are not expected to be cleared 
through glomerular filtration. Therefore, unlike other imag-
ing agents that undergo renal clearance (eg iodinated x-ray 
contrast agents, gadolinium-based MR contrast agents), PFC 
emulsions are not immediately considered as nephrotoxic, 
thereby holding promise for in vivo tissue pO2 assessment 
of renal tissue in animal models of AKI.92
One of the most exciting areas of innovation in biomedi-
cal imaging concerns the visualization on multiple scales in 
space and time: imaging biological objects in size ranging 
from the atomic to the anatomic scale, and from nanoseconds 
to decades in large population imaging studies.96 Advances 
in biomedical imaging have spurred developments and ap-
plications in the fields of optical, high-frequency ultra-sound 
and photoacoustic imaging.97 The progress in photoacoustic 
imaging provides a trajectory into the characterization of 
(patho)physiological conditions of the kidney, which could 
allow early detection of kidney injury owing to its capacity 
to probe renal oxygen saturation of haemoglobin.98 This de-
velopment underlines the potential and value of hybrid and 
complementary modalities in basic research and clinical sci-
ence, such as optoacoustic imaging and MRI, photoacoustic 
imaging and intravital 2-photon microscopy or near infrared 
spectroscopy (NIRS) and MRI,40 and their calibration with 
quantitative gold standards.96
9 |  CONCLUSION
We should definitely not skip BOLD for renal imaging. What 
we need to do is to re-evaluate our understanding of BOLD 
imaging as validated bio- or imaging marker for renal tissue 
oxygenation. For this, we (only) need to decipher and quan-
tify the changes in the vascular and tubulus volume fraction 
that are confounding BOLD imaging. This calibration will 
empower BOLD imaging and its application in the research 
setting and in the clinical arena. It can be expected that there 
are several (patho)physiological conditions in which the 
knowledge of BVf will not be as essential (eg in early stage 
diabetes) as for other more complex scenarios (eg in kidney 
transplantation). These considerations are necessary to make 
valid statements about renal blood oxygenation, especially 
in cases where BVf is not significantly different from the 
normal healthy physiological condition. It still remains to 
be determined whether errors introduced by ignoring BVf in 
specific settings remain within acceptable error margins or 
not.
To conclude, further weight should be put behind the solu-
tion of the remaining issues to advance the (pre)clinical value 
and the capabilities of parametric MRI for probing dynamic 
changes in the renal blood volume with the goal to decipher 
the confounding impact of the vascular compartment on T2* 
en route to improving our understanding of haemodynamics/
oxygenation in kidney disorders. A swift transfer of MR ox-
imetry, including T2* mapping and renal BVf quantification, 
from the research scenario into the clinic should be targeted 
in interdisciplinary and interinstitutional collaboration net-
works among forward-thinking basic researchers, application 
scientists and clinicians to establish a comprehensive MR 
protocol for the in vivo and non-invasive assessment of renal 
haemodynamics and oxygenation. As this approach may be-
come increasingly used in (pre)clinical research, it should 
help to enhance the potential of MRI for the assessment of 
renal diseases.
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